FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* WILLIAMS KRISTEN					2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]										ck all app Direc	licable) tor	ng Pe	erson(s) to Is	wner
(Last)	Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/12/2024									belov	Officer (give title below)  Chief Administra		Other (below)	·
5401 WEST KENNEDY BOULEVARD, SUITE 890						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Form filed by One Reporting Person				
(Street) TAMPA	` '				Rul	Rule 10b5-1(c) Transaction Indication											orting		
(City)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Table	I - No	n-Deriva	tive S	Secui	rities	Acc	uired	, Dis	posed of	, or E	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execu	eemed ition Date, h/Day/Year)		Transaction D		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Securi Benefi Owned	5. Amount of Securities Beneficially Owned Following Reported		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(111511.4)
Common Stock 06/12/2						024					54,300(1)	) A		<b>\$0</b>	110,364			D	
Common Stock 06/13/2						.024			S <sup>(2)</sup>		7,452	D	9	\$28.38	102,912			D	
		Tal	ole II -								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)		ansaction ode (Instr.		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercition Da h/Day/Y		7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		De Se (In	Price of erivative curity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of

## Remarks:

/s/ Kristen Williams

06/13/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.